Skip to main
DYN
DYN logo

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics Inc. has demonstrated promising clinical improvements in its therapeutic programs, particularly with DYNE-251, which has shown sustained enhancements in key clinical endpoints, including the North Star Ambulatory Assessment (NSAA) and timed walking tests. The company's FORCE platform exhibits potential advantages in delivering targeted therapeutics, which may enhance treatment outcomes for neuromuscular diseases, notably with a successful increase in dystrophin expression as indicated by a 3.27% increase in exon 51 skipping. Additionally, the favorable safety profile of DYNE-251, with no significant increases in treatment-related adverse events, underscores the potential for regulatory approval, positioning the company favorably within the biotech landscape.

Bears say

Dyne Therapeutics faces several challenges that contribute to a negative outlook on its stock. The results of ongoing and future clinical trials for its RNA-based therapeutics present significant risk; failures to achieve clinical endpoints can lead to substantial downward pressure on share prices. Additionally, high patient discontinuation rates, coupled with advancements in competitive treatment methods and potential issues surrounding intellectual property protection, further jeopardize the company’s market position and overall viability.

Dyne Therapeutics (DYN) has been analyzed by 26 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 26 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Sep 21, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.52, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.